Self Adjuvanting CTL-Based Influenza Vaccines for Human Use

人用基于 CTL 的自我辅助流感疫苗

• 批准号: nhmrc : 400580
• 负责人: Dr Weiguang Zeng
• 金额: $ 14.33万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Strategic Awards
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-01-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/self-adjuvanting-ctl-human-use/96050
• 关键词: Self; Adjuvanting; CTL; Based; Influenza

This project will generate novel vaccines that elicit cell-mediated immunity against influenza infection. The vaccines are totally synthetic and therefore not constrained by the limitations in manufacturing which currently confront egg-grown vaccines. These vaccines induce very strong immune responses because they target dendritic cells which are pivotal for induction of all immune responses. This targeting capability is due to a simple lipid molecule incorporated into the vaccine which is recognised by specific receptors on the surface of dendritic cells and also causes their maturation, a step which is essential for recognition by the immune system of potential pathogens. The technology to design and assemble these new vaccines is already.

该项目将产生新型疫苗，引发针对流感感染的细胞介导免疫。这些疫苗是完全合成的，因此不受目前鸡蛋生长疫苗所面临的制造限制的限制。这些疫苗诱导非常强的免疫应答，因为它们靶向树突细胞，树突细胞对于诱导所有免疫应答是关键的。这种靶向能力是由于掺入疫苗中的简单脂质分子，该脂质分子被树突细胞表面上的特异性受体识别，并且还导致其成熟，这是免疫系统识别潜在病原体所必需的步骤。设计和组装这些新疫苗的技术已经成熟。